MENU
+Compare
IMUX
Stock ticker: NASDAQ
AS OF
Jul 10, 04:59 PM (EDT)
Price
$0.84
Change
+$0.01 (+1.20%)
Capitalization
77.21M

IMUX Immunic Forecast, Technical & Fundamental Analysis

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMUX with price predictions
Jul 09, 2025

IMUX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IMUX turned positive on July 02, 2025. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMUX's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 07, 2025. You may want to consider a long position or call options on IMUX as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMUX broke above its upper Bollinger Band on July 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMUX entered a downward trend on June 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.998) is normal, around the industry mean (17.327). P/E Ratio (0.000) is within average values for comparable stocks, (59.374). IMUX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.418). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (272.335).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMUX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMUX is expected to report earnings to fall 31.60% to -17 cents per share on August 07

Immunic IMUX Stock Earnings Reports
Q2'25
Est.
$-0.17
Q1'25
Missed
by $0.03
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.02
The last earnings report on May 08 showed earnings per share of -25 cents, missing the estimate of -22 cents. With 648.71K shares outstanding, the current market capitalization sits at 77.21M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYSNY3.860.24
+6.64%
Hysan Development Co., Ltd.
RECAF0.33N/A
+0.54%
Reconnaissance Energy Africa Ltd.
SPRS2.27N/A
N/A
Surge Components, Inc.
TRATF32.96N/A
N/A
Traton SE
FMCKI11.16-0.22
-1.91%
Freddie Mac

IMUX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with NTLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-2.82%
NTLA - IMUX
40%
Loosely correlated
+9.08%
PLRX - IMUX
36%
Loosely correlated
+14.29%
OABI - IMUX
36%
Loosely correlated
+6.28%
RXRX - IMUX
35%
Loosely correlated
+4.29%
ERAS - IMUX
35%
Loosely correlated
+5.48%
More